[1] 白文娣, 蔡微, 陈仕锋, 等.以新型冠状病毒肺炎为例浅析血浆疗法的现况及发展[J/OL].病毒学报.https://doi.org/10.13242/j.cnki.bingduxuebao.003672. [2] Wong HK, Lee CK, Hung IF, et al.Practical limitations of convalescent plasma collection:a case scenario in pandemic preparation for influenza A (H1N1) infection[J].Transfusion, 2010, 50(9):1967-1971. [3] World Health Organization. Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease for transfusion, as an empirical treatment during outbreaks[EB/OL]. (2014) Available at https://apps.who.int/iris/bitstream/handle/10665/135591/WHO_HIS_SDS_2014.8_eng.pdf?sequence=1. [4] 郭永建. WHO埃博拉病毒病暴发流行期间的经验治疗—埃博拉病毒病康复者全血或血浆使用指引及启示[J].中国输血杂志, 2015, 28(3):342-347. [5] World Health Organization.WHO Blood Regulators Network Position Paper on Use of Convalescent Plasma, Serum or Immune Globulin Concentrates as an Element in Response to an Emerging Virus (2017)[EB/OL]. Available athttps://www.who.int/bloodproducts/brn/2017_BRN_PositionPaper_ConvalescentPlasma.pdf?ua=1. [6] 国家卫生健康委员会.关于印发新型冠状病毒肺炎诊疗方案(试行第七版)的通知[EB/OL].[2020-03-04].http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml. [7] 国家卫生健康委员会.关于印发新冠肺炎康复者恢复期血浆临床治疗方案(试行第二版) 的通知[EB/OL].[2020-03-04].http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml. [8] Tanne JH.Covid-19:FDA approves use of convalescent plasma to treat critically ill patients[J].BMJ, 2020, 368:m1256. [9] FDA.Investigational covid-19 convalescent plasma-emergency INDs[EB/OL].https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ideprocess-cber/investigational-covid-19-convalescent-plasma-emergency-inds. [10] Center for Biologics Evaluation and Research.Investigational COVID-19 convalescent plasma -emergency INDs 26 March2020[EB/OL]. Available at: https://www.fda. gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemptionide-process-cber/investigational-covid-19-convalescent-plasma-emergency-inds. [11] Coronavirus Disease2019(COVID-19) Treatement Guidelines[EB/OL].https://covid19treatmentguidelines.nih.gov/ [12] 李泉, 刘钉宾, 乔正荣, 等.SARS-CoV-2 IgM/IgG抗体检测在新型冠状病毒肺炎诊断中的价值[J/OL].国际检验医学杂志.http://kns.cnki.net/kcms/detail/50.1176.r.20200304.1041.006.html. [13] Bloch E M, Shoham S, Casadevall A, et al.Deployment of convalescent plasma for the prevention and treatme 14 nt of COVID-19[J].J Clin Invest, 2020, 130(6):2757-2765. [14] Yao XH, He ZC, Li TY, et al.Pathological evidence for residual SARS-CoV-2 in pulmonary tissues of a ready-for-discharge patient[J].Cell Res, 2020, 30(6):541-543. [15] Jianghong An, Xuejiao Liao, Tongyang Xiao, et al. Clinical characteristics of the recovered COVID-19 patients with re-detectable positive RNA test[J].medrxiv. https://doi.org/10.1101/2020.03.26.20044222. [16] 中国输血协会临床输血管理学委员会.2019新型冠状病毒肺炎防控期间临床输血血型血清学实验室生物安全防护指南(第二版)[J].临床输血与检验, 2020, 22(03):225-228. [17] Brown JF, Rowe K, Zacharias P, et al.Apheresis for collection of Ebola convalescent plasma in Liberia[J].J Clin Apher, 2017, 32(3):175-181. [18] Geisen C, Kann G, Strecker T, et al.Pathogen-reduced Ebola virus convalescent plasma:first steps towards standardization of manufacturing and quality control including assessment of Ebola-specific neutralizing antibodies[J].Vox Sang, 2016, 110(4):329-335. [19] 陈富强, 朱海峰, 肖晨, 等.新型冠状病毒康复者血浆IgM和IgG不同试剂检测结果的差异分析[J].临床输血与检验, 2020, 22(3):258-263. [20] 张立波, 戴宇东, 庞蓉蓉, 等.血站实验室新型冠状病毒相关检测平台的建立与安全防护[J].临床输血与检验, 2020, 22(03):246-249. [21] 李营, 张树超, 张少强, 等.康复者血浆治疗新型冠状病毒肺炎疗效分析1例[J/OL].临床输血与检验.http://kns.cnki.net/kcms/detail/34.1239.R.20200415.1851.002.html. [22] Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al.Treatment of 5 critically ill patients with COVID-19 with convalescent plasma[J]. JAMA.2020, Treatment of 5 critically ill patients with COVID-19 with convalescent plasma[J]. JAMA.2020, http://dx.doi.org/10.1001/jama.2020.4783. [23] Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients[J]. ProcNatlAcadSci U S A2020. https://doi. org/10.1073/pnas.2004168117. [24] Zhang B, Liu S, Tan T, Huang W, Dong Y, Chen L, et al.Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection[J]. Chest 2020. https://doi. org/10.1016/j.chest.2020.03.039. [25] Arabi Y, Balkhy H, Hajeer A H, et al.Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection:a study protocol[J].Springerplus, 2015, 4:709. [26] 徐研, 洪缨, 万浬科, 等.成都地区女性献血者HLA抗体分布[J].中国输血杂志, 2014, 27(9):943-945. [27] 安宁, 张秋会, 夏爱军, 等.西安地区女性献血者HLA抗体筛查分析[J].临床输血与检验, 2016, 18(6):568-570. [28] 徐秀章, 夏文杰, 陈大伟, 等.广州地区无偿献血者HLA抗体及HNA-3a抗体检测分析[J].中国输血杂志, 2015, 28(11):1337-1339. [29] Bosboom JJ, Klanderman RB, Migdady Y, et al.Transfusion-associated circulatory overload:a clinical perspective[J].Transfus Med Rev, 2019, 33(2):69-77. [30] Zheng YY, Ma YT, Zhang JY, et al.COVID-19 and the cardiovascular system[J].Nat Rev Cardiol, 2020, 17(5):259-260. [31] Shi SB, Qin M, Shen B, et al.Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China[J].JAMA Cardiol, 2020, 5(7):802-810. [32] Semple JW, Rebetz J, Kapur R.Transfusion-associated circulatory overload and transfusion-related acute lung injury[J].Blood, 2019, 133(17):1840-1853. [33] Wiersum-Osselton JC, Whitaker B, Grey S, et al.Revised international surveillance case definition of transfusion-associated circulatory overload:a classification agreement validation study[J].Lancet Haematol, 2019, 6(7):e350-e358. [34] Smatti MK, Al Thani AA, Yassine HM.Viral-induced enhanced disease illness[J].Front Microbiol, 2018, 9:2991. [35] Zhang LQ, Zhang FW, Yu WJ, et al.Antibody responses against SARS coronavirus are correlated with disease outcome of infected individuals[J].J Med Virol, 2006, 78(1):1-8. [36] To KK, Tsang OT, Leung WS, et al.Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2:an observational cohort study[J].Lancet Infect Dis, 2020, 20(5):565-574. [37] Zhao JJ, Yuan Q, Wang HY, et al.Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019[J].Clin Infect Dis, 2020:ciaa344. [38] Fu YJ, Cheng YX, Wu YT.Understanding SARS-CoV-2-mediated inflammatory responses:from mechanisms to potential therapeutic tools[J].Virol Sin, 2020, 35(3):266-271. [39] Arabi YM, Hajeer AH, Luke T, et al.Feasibility of using convalescent plasma immunotherapy for MERS-CoVinfection, Saudi Arabia[J].Emerging Infect Dis, 2016, 22(9):1554-1561. |